Genflow Biosciences plc (LON:GENF, OTCQB:GENFF, FRA:WQ5) is a UK-based biotech firm with R&D facilities in Belgium focused on developing novel therapeutic approaches that potentially halt or slow the aging process in humans and dogs supporting longer, healthier lives. Genflow Biosciences’ lead compound, GF-1002 operates through the delivery of a centenarian variant of the SIRT6 gene. This gene, identified in individuals who reach the age of 100 or beyond, has demonstrated promising preclinical results.
First in human proof-of-concept Phase I/ II Trial in MASH
MASH or Metabolic Dysfunction-Associated Steatohepatitis (MASH) is a liver disease with a significant unmet medical need. Effecting an estimated 35 million people worldwide, it is the most chronic liver condition in the West and patient numbers are growing rapidly. It is the leading cause of liver transplants due to the lack of approved therapies with the market for MASH therapy expected to reach $27.2B by 2029. Recent pre-clinical programs have highlighted the adipogenic, anti-fibrotic, and anti-tumoral effects of GF-1002 positioning it as a promising treatment candidate for MASH. By targeting MASH, Genflow Biosciences stands to benefit from a clear regulatory pathway that could lead to accelerated development and the potential for conditional fast-track approval.
